Read by QxMD icon Read

Breast Cancer: Basic and Clinical Research

Yuichiro Kikawa, Takeshi Kotake, Yukiko Kajiwara, Kazuki Hashimoto, Hiroyasu Yamashiro, Shoichiro Ohtani, Shintaro Takao, Masakazu Toi
Purpose: To investigate the clinical predictive factors for the efficacy of everolimus (EVE) for advanced/metastatic breast cancer (AMBC). Methods: Routine practice data of consecutive patients with AMBC who received EVE at 5 institutions in western Japan were retrospectively analyzed in this cohort study (study registration no.: UMIN 000032569). The correlation among time to treatment failure (TTF), overall survival (OS), and clinical background was investigated via univariate and multivariate analyses using Cox hazards model for the clinically important variables...
2019: Breast Cancer: Basic and Clinical Research
JungSun Lee, Minkyung Oh, SeungSang Ko, Chanheun Park, Eun Sook Lee, Hyun-Ah Kim, Yongsik Jung, Jungyeon Lee
Purpose: Multiparity might increase general mortality for women, but has inconclusive in patients with breast cancer. Here, we aim to discover their effect in terms of the breast cancer development hypothesis: from ductal carcinoma in situ to invasive carcinoma. Methods: We included 37 947 patients from the web-based breast cancer registration program of the Korean Breast Cancer Society and analyzed survivals using multivariate Cox regression analysis and whether the associations of these factors displayed linear trends...
2019: Breast Cancer: Basic and Clinical Research
Tam Binh V Bui, Desirée Mt Burgers, Mariette J Agterof, Ewoudt Mw van de Garde
Objective: The aim of this study was to assess the real-world effectiveness and tolerability of palbociclib combined with endocrine therapy for the treatment of hormone receptor positive (HR-positive), human epidermal growth factor receptor 2 negative (HER2-negative), advanced/metastatic breast cancer that progressed on previous endocrine therapy, and to compare these results with the outcomes of the PALOMA-3 clinical trial. Methods: This study was a retrospective observational cohort study including all patients who started with palbociclib in the St...
2019: Breast Cancer: Basic and Clinical Research
Muhammad Arif, Hamid Raza, Muhammad Sohail Afzal
No abstract text is available yet for this article.
2018: Breast Cancer: Basic and Clinical Research
(no author information available yet)
[This corrects the article on p. 35 in vol. 4, PMID: 20697531.].
2018: Breast Cancer: Basic and Clinical Research
Vanina D Heuser, Naziha Mansuri, Jasper Mogg, Samu Kurki, Heli Repo, Pauliina Kronqvist, Olli Carpén, Maria Gardberg
Basal-like breast cancer is an aggressive form of breast cancer with limited treatment options. The subgroup can be identified immunohistochemically, by lack of hormone receptor expression combined with expression of basal markers such as CK5/6 and/or epidermal growth factor receptor (EGFR). In vitro, several regulators of the actin cytoskeleton are essential for efficient invasion of basal-like breast cancer cell lines. Whether these proteins are expressed in vivo determines the applicability of these findings in clinical settings...
2018: Breast Cancer: Basic and Clinical Research
Yanal Alnimer, Zakaria Hindi, Khalil Katato
Introduction: Multiple trials demonstrated that adding Bevacizumab to the standard neoadjuvant chemotherapy in HER-2 negative breast cancer increases pathological complete response. We conducted this meta-analysis to evaluate that effect on survival. Methods: We performed a systematic search for randomized trials measuring the effect of adding either neoadjuvant or adjuvant Bevacizumab to the standard chemotherapy on disease-free and overall survival in breast cancer surgical candidates...
2018: Breast Cancer: Basic and Clinical Research
Shaimaa Elzamly, Nabeel Badri, Osvaldo Padilla, Alok Kumar Dwivedi, Luis A Alvarado, Matthew Hamilton, Nabih Diab, Crosby Rock, Ahmed Elfar, Marwa Teleb, Luis Sanchez, Zeina Nahleh
The association between pathologic complete response (pCR) following to neoadjuvant chemotherapy (NAC) and the improved survival in breast cancer has been previously reported. The aim of this study was is to explore the expression of several biomarkers described during epithelial-mesenchymal transition (EMT) and the achievement of pCR in different molecular subtypes of breast cancer. We identified archived pathology tissue from patients with breast cancer who received NAC during the year 2014. We performed immunohistochemical analysis of vimentin, nuclear factor κB (NF-κB), epidermal growth factor receptor (EGFR), E-cadherin, estrogen receptor (ER), progesterone receptor, and Her2neu and studied the association between the expression of these markers and pCR...
2018: Breast Cancer: Basic and Clinical Research
Jeison Garcia, Fernando Lizcano
Members of the jumonji-containing lysine demethylase protein family have been associated with cancer development, although their specific roles in the evolution of tumor cells remain unknown. This work examines the effects of lysine demethylase 4C (KDM4C) knockdown on the behavior of a triple-negative breast cancer cell line. KDM4C expression was knocked-down by siRNA and analyzed by Western blot and immunofluorescence. HCC38 cell proliferation was examined by MTT assay, while breast cancer cells' migration and invasion were tested in Transwell format by chemotaxis...
2018: Breast Cancer: Basic and Clinical Research
Hiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, Yasuhiro Okumura, Toshimi Takano, Eriko Tokunaga, Tsuyoshi Saito, Yasuaki Sagara, Kosuke Yamazaki, Yoshihiro Kawaguchi, Tecchuu Lee, Shinji Ozaki, Kazuhiko Yamagami, Naohito Yamamoto, Katsumasa Kuroi, Hirofumi Suwa, Shoichiro Ohtani, Toshikazu Ito, Shinji Yasuno, Satoshi Morita, Shinji Ohno, Masakazu Toi
Background: There are little data on the usefulness of trastuzumab (TZM) retreatment as the first-line treatment for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer recurrence after perioperative treatment with TZM. Aim: To clarify the outcome and safety of TZM retreatment in patients with recurrent HER2-positive breast cancer. Method: An observational study was conducted on patients who relapsed after primary systemic therapy with TZM using the central registration system...
2018: Breast Cancer: Basic and Clinical Research
Jennifer J Salinas, Theresa Byrd, Charmaine Martin, Alok K Dwivedi, Adam Alomari, Rebekah Salaiz, Navkiran K Shokar
Purpose: To determine the relationship between breast cancer screening knowledge and intent to receive a mammogram within 6 months in a sample of Mexican-origin women living in El Paso, Texas. Methods: A total of 489 uninsured Mexican-origin women were assigned to treatment or control and completed surveys at pre- and postintervention. Pre-post associations between breast cancer screening knowledge and intent were tested. Results: Participants were on average were 56...
2018: Breast Cancer: Basic and Clinical Research
Issam Makhoul, Mohammad Atiq, Ahmed Alwbari, Thomas Kieber-Emmons
The immune system plays a major role in cancer surveillance. Harnessing its power to treat many cancers is now a reality that has led to cures in hopeless situations where no other solutions were available from traditional anticancer drugs. These spectacular achievements rekindled the oncology community's interest in extending the benefits to all cancers including breast cancer. The first section of this article reviews the biological foundations of the immune response to different subtypes of breast cancer and the ways cancer may overcome the immune attack leading to cancer disease...
2018: Breast Cancer: Basic and Clinical Research
Chloe C Kimball, Christine I Nichols, Joshua G Vose
Objectives: Percutaneous core-needle biopsy (PCNB) is the standard of care to biopsy and diagnose suspicious breast lesions. Dependent on histology, many patients require additional open procedures for definitive diagnosis and excision. This study estimated the payer and patient out-of-pocket (OOP) costs, and complication risk, among those requiring at least 1 open procedure following PCNB. Methods: This retrospective study used the Truven Commercial database (2009-2014)...
2018: Breast Cancer: Basic and Clinical Research
Danielle Tippit, Eric Siegel, Daniella Ochoa, Angela Pennisi, Erica Hill, Amelia Merrill, Mark Rowe, Ronda Henry-Tillman, Aneesha Ananthula, Issam Makhoul
Most of the patients undergoing treatment for cancer require placement of a totally implantable venous access device to facilitate safe delivery of chemotherapy. However, implantable ports also increase the risk of deep vein thrombosis and related complications in this high-risk population. The objective of this study was to assess the incidence of upper-extremity deep vein thrombosis (UEDVT) in patients with breast cancer to determine whether the risk of UEDVT was higher with chest versus arm ports, as well as to determine the importance of previously reported risk factors predisposing to UEDVT in the setting of active cancer...
2018: Breast Cancer: Basic and Clinical Research
Joshua Weir, Yan Daniel Zhao, Terence Herman, Özer Algan
Male breast cancer (MBC) accounts for approximately 1% of all breast cancers, limiting the data characterizing clinicopathologic features and treatment outcomes in patients with MBC. This paucity of data has led to most of our treatment guidance being extrapolated from patients with female breast cancer (FBC). From 1998 to 2012, data were captured using the National Cancer Database to identify patients with nonmetastatic MBC (n = 23 305) and FBC (n = 2 678 061). Tumor and clinicopathologic features were obtained and compared...
2018: Breast Cancer: Basic and Clinical Research
Junya Peng, Wenqian Wang, Surong Hua, Lulu Liu
Cells can secrete extracellular vesicles (EVs) to communicate with neighboring or distant cells by EVs which are composed of a lipid bilayer containing transmembrane proteins and enclosing cytosolic proteins, lipids, and nucleic acids. Breast Cancer is the most frequently diagnosed malignancy with more than 1 million new cases each year and ranks the leading cause of cancer mortality in women worldwide. In this review, we will discuss recent progresses of the roles and mechanisms of cancer-derived EVs in metastatic breast cancer, with a special attention on tumor microenvironment construction, progression, and chemo/radiotherapy responses...
2018: Breast Cancer: Basic and Clinical Research
Afsaneh Alikhassi, Seyedeh Nooshin Miratashi Yazdi, Hedieh Akbari, Sona Akbari Kia, Masoud Baikpour
Objective: Breast cancer is the most common malignancy in the female population, and imaging studies play a critical role for its early detection. Mammographic breast density (MBD) is one of the markers used to predict the risk stratification of breast cancer in patients. We aimed to assess the correlations among MBD, ultrasound breast composition (USBC), fibroglandular tissue (FGT), and the amount of background parenchymal enhancement (BPE) in magnetic resonance imaging, after considering the subjects' menopausal status...
2018: Breast Cancer: Basic and Clinical Research
Igor Motuzyuk, Oleg Sydorchuk, Natalia Kovtun, Zinaida Palian, Yevhenii Kostiuchenko
Background: The study aims to evaluate the current state and tendencies in multiple primary breast cancer incidence, behavior, and treatment in Ukraine. Methods: A total of 2032 patients who received special treatment at the Department of Breast Tumors and Reconstructive Surgery of the National Cancer Institute from 2008 to 2015 were included in the study. Among them, there were 195 patients with multiple primary malignant neoplasms: 54.9% patients with synchronous cancer and 45...
2018: Breast Cancer: Basic and Clinical Research
Gloria Richard-Davis, Brianna Whittemore, Anthony Disher, Valerie Montgomery Rice, Rathinasamy B Lenin, Camille Dollins, Eric R Siegel, Hari Eswaran
Objective: Increased mammographic breast density is a well-established risk factor for breast cancer development, regardless of age or ethnic background. The current gold standard for categorizing breast density consists of a radiologist estimation of percent density according to the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) criteria. This study compares paired qualitative interpretations of breast density on digital mammograms with quantitative measurement of density using Hologic's Food and Drug Administration-approved R2 Quantra volumetric breast density assessment tool...
2018: Breast Cancer: Basic and Clinical Research
John Syrios, Evelina Pappa, Nikolaos Volakakis, Anastasios Grivas, John Alafis, Sofia Manioudaki, Vasiliki Tzouda, Athanasios Korogiannos, Cleopatra Rapti, Nektarios Koufopoulos, Adamantia Nikolaidou, Eleftheria Kanavou, Athanasios Alexopoulos, Anna Koumarianou
Purpose: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (anti-HER2) antibody delivered intravenously, has revolutionized the treatment of patients with breast cancer overexpressing HER2 protein. Recently, a newer subcutaneous formulation was shown to have comparable efficacy to the initial intravenous trastuzumab. In this study, we aimed to evaluate the impact of subcutaneous trastuzumab on the health-related quality of life (HRQoL) of patients diagnosed with early or metastatic HER2-overexpressing breast cancer...
2018: Breast Cancer: Basic and Clinical Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"